1

A high throughput Cre–lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry

A.M.Esposito, P.Cheung, T.H. Swartz, H.Li, T.Tsibane, N.D.Durham, C.F.Basler, D.P.Felsenfeld, B.K.Chen

Virology. (2016) pp. 6–16. doi: 10.1016/j.virol.2015.10.013

 

2

Expression of human immunodeficiency virus type 1 Neutralizing antibody fragments using human Vaginal Lactobacillus

A.Marcobal, X.Liu, W.Zhang, A.S.Dimitrov, L.Jia, P.P.Lee, T.R.Fouts, T.P.Parks, L.A.Lagenaur

AIDS Research and Human Retroviruses. (2016) pp.1-8  doi: 10.1089/aid.2015.0378.

 

3

Development of broadly neutralizing antibodies and their mapping by monomeric gp120 in HIV-1 infected humans and SHIVSF162P3N infected macaques

M.Jia, H.Lu, M.Markowitz, C.Cheng-Mayer

Journal of Virology. (2016) pp. 15–2898. doi: 10.1128/JVI.02898-15.

 

4

Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites

S.Townsley, Y.Li,  Y.Kozyrev, B.Cleveland, S-L.Hu

J. Virol. (2016) vol. 90 (2) p. 829-841

 

5

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice

A.T.McGuire, M.D.Gray, P.Dosenovic, A.D.Gitlin, N.T.Freund, J.Petersen, C.Correnti, J.William, R.Kegel, A.B.Stuart, J.Glenn, M.S.Seaman, W.R.Schief, R.K.Strong, M.C.Nussenzweig, L.Stamatatos

Nature Communications (2016) vol. 7 p. 10618

 

6

Lambda Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies

M.M.Sajadi, M.Farshidpour, E.P.Brown, X.Ouyang, M.S.Seaman, M.Pazgier, M.E.Ackerman, H.Robinson, G.Tomaras, M.S.Parsons, M.Charurat, R.R.Redfield, G.K.Lewis.

The Journal of Infectious Disease (2016) vol. 213 (1) p. 156-164

 

7

Lipidic Cubic Phases as a Versatile Platform for the Rapid Detection of Biomarkers, Viruses, Bacteria, and Parasites

J.J.Vallooran, S.Handschin, S.M.Pillai, B.N.Vetter, S.Rusch, B.Hans-Peter, M.Raffaele.

Advanced Functional Materials (2016) vol. 26 (2) p. 181-190

 

8

Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.

 

K.Sliepen, M.Medina-Ram�rez,  A.Yasmeen, J.P.Moore, P.J.Klasse, R.W.Sanders.

 

Virology (2015) vol. 486 p. 116-20

 

 

9

Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens.

 

J-P.Julien,  J.H.Lee, G.Ozorowski, Y.Hua, A.Torrents de la Pe�a,  S.W.de Taeye, T.Nieusma, A.Cupo, A.Yasmeen,

M.Golabek, P.Pugach, P.J.Klasse, J.P.Moore, R.W.Sanders, A.B.Ward, I.A.Wilson.

 

Proceedings of the National Academy of Sciences of the United States of America (2015) vol. 112 (38) p. 11947-52

 

 

10

A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene.

P.Pugach, G.Ozorowski, A.Cupo, R.Ringe, A.Yasmeen, N.de Val, R.Derking, H.J.Kim, J.Korzun,  M.Golabek, K.de los Reyes, T.J.Ketas, JPJulien, D.R.Burton, I.A.Wilson, R.W.Sanders, P.J.Klasse, A.B.Ward, J.P.Moore.

J. Virol. (2015) vol. 89 (6) p. 3380-3395

 

11

A Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer.

R.Derking, G. Ozorowski, K.Sliepen, A.Yasmeen, A.Cupo, J.L.Torres, J-P. Julien, J.H. Lee, T.van , Montfort, S.W.de Taeye, M.Connors, D.R.Burton, I.A.Wilson, P-J.Klasse, A.B.Ward, J.P.Moore,

R.W.Sanders.

PLOS Pathog. (2015) vol. 11 (3) p. e1004767

 

12

Different infectivity of HIV-1 Strains is Linked to Number of Envelope Trimers Required for Entry.

O.F.Brandenberg, C.Magnus, P.Rusert, R.R.Regoes, A.Trkola

PLOS Pathog. (2015) vol. 11 (1) p. e1004595

 

13

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
J.H.Lee, D.P.Leaman, A.S.Kim, A.T.de la Pe�a, K.Sliepen, A.Yasmeen, R.Derking, A.Ramos, S.W.de Taeye, G.Ozorowski, F.Klein, D.R.Burton, M.C. Nussenzweig, P.Poignard, J.P.Moore, P.J.Klasse, R.W.Sanders, M.B.Zwick, I.A.Wilson, A.B.Ward

Nature Communications (2015) vol. 6

 

14

Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity

K.Sliepen, G.Ozorowski, J.A.Burger, T.van Montfort, M.Stunnenberg, C.Labranche, D.C.Montefiori, J.P.Moore, A.B.Ward, R.W.Sanders

Retrovirology (2015) vol. 12 (1) p. 82

 

15

Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

J.H.Lee, C.Blattner, A.Ramirez, R.Derking, M.J.van Gils, C-H.Liang, R.Mcbride, B.von Bredow, S.S.Shivatare, C-Y.Wu, P-Y.Chan-Hui, Y.Liu, T.Feizi, M.B.Zwick, W.C.Koff, M.S.Seaman, K.Swiderek, J.P.Moore, D.Evans, J.C.Paulson,C-H.Wong, A.B.Ward, L.A.Wilson,R.W.Sanders, P.Poignard, D.R.Burton.

Immunity (2014) vol. 40 (5) p. 657-68

 

16

A next-generation cleaved, soluble HIV-1 env trimer, BG505 SOSIP. 664 gp120, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

R.W.Sanders, R.Derking, A.Cupo, J-P.Julien, A.Yasmeen, N.de Val, H.J. Kim, C.Blattner, A. T. de la Pe�a, J.Korzun, M.Golabek, K. de los Reyes, T.J.Ketas, M.J.van Gils, C.R.King, I.A.Wilson, A.B. Ward, P.J.Klasse, J.P.Moore.

PLoS Pathogens (2013): vol. 9 (9) p. e1003618

 

17

Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells.

Amanda M. Micsenyi, Chati Zony, Raymond A. Alvarez, Natasha D. Durham, Benjamin K. Chen, Mary E. Klotman. A.M.Micsenyi, C.Zony, R.A.Alvarez, N.D.Durham, B.K.Chen, M.E.Klotman.

The Journal of Infectious Diseases (2013) : vol. 208 (11) p. 1756-67

 

18

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.

A.T.McGuire, S.Hoot, A.M.Dreyer, A.Lippy, A.Stuart, K.W.Cohen, J.Jardine, S.Menis, J.F.Scheid, A.P.West, W.R.Schief, L.Stamatatos.

The Journal of Experimental Medicine (2013) : vol. 210 (4) p. 655-63

 

19

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

R.P.Ringe, R.W.Sanders,A.Yasmeen, H.J.Kim, J.H.Lee, A.Cupo, J.Korzun, R.Derking, T.van Montfort, J-P.Julien, I.A.Wilson, P.J.Klasse, A.B.Ward, J.P.Moore.

The Journal of Experimental Medicine (2013) : vol. 210 (4) p. 655-63 (2013).

 

20

Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae.

L.Furci, M.Tolazzi, F.Sironi, L.Vassena, P.Lusso.

PloS One (2012) : vol. 7 (9) p. e45208

 

21

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

P-F.Lin, W.Blair, T.Wang, T.Spicer, Q.Guo, N.Zhou, Y-F.Gong, H.H-G.Wang, R.Rose, G.Yamanaka,B.Robinson, C-B.Li, R.Fridell, C.Deminie, G.Demers, Z.Yang, L.Zadjura,N.Meanwell, R.Colonno.

Proceedings of the National Academy of Sciences of the U.S. (2003) : Vol 100, no.19, 11013-11018.

 

22

Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.

T.L-Y.Chang, C-H.Chang, D.A.Simpson, Q.Xu, P.KMartin, L.A.Lagenaur, G.K.Schoolnik, D.D.Ho, S.L.Hillier, M.Holodniy, J.A.Lewicki, P.P.Lee.

Proceedings of the National Academy of Sciences of the U.S. (2003) : Vol.100, no.20, 11672-11677

 

23

Characterisation of Infectious Retroviral Pseudotype Particles bearing Hepatitis C Virus Glycoproteins.

Mike Flint, Carine Logvinoff, Charles M.Rice, Jane A.McKeating.

J.Virol. (2004) ; 78(13): 6875-6882

 

24

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small molecule CCR5 inhibitor.

S.E.Kuhmann, P.A.Pugach, K.Kunstman, J.Taylor, R.Stansfield, A.Snyder, J.M.Strizki, J.Riley, B.M.Baroudy, I.A.Wilson, B.T.Korber, S.M.Wolinsky, J.P.Moore.

J.Virol (2004) : 78, 2790-2807

 

25

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralisation by soluble CD4.

P.Pugach, S.E.Kuhmann, J.Taylor, A.J.Marozsan, A.Snyder, T.Ketas, S.M.Wolinsky, B.T.Korber, J.P.Moore.

Virology (2004) : 321, 8-22.

 

26

Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes 

L. Martin, F. Stricher, D. Misse, F. Sironi, M. Pugniere, P. Barthe, R. Prado-Gotor, I. Freulon, X. Magne, C. Roumestand, A. Menez, P. Lusso, F. Veas, C. Vita. 

Nature Biotechnol. (2003): 21, 71-76.

 

27

Nonneutralising antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralising antibody against the same site.

C.Herrera, C.Spenlehauer, M.S.Fung, D.R.Burton, S.Beddows, J.P.Moore.

J.Virol (2003) : 77, 1084-1091

 

28

Protein-disulfide isomerase –mediated reduction of two disulfide bonds of HIV Envelope Glycoprotein 120 occurs post-CXCR4 binding and is required for fusion.

R.Barbouche, R.Miquelis, Ian Jones, Emmanuel Fenouillet.

J.Biol.Chem (2003) : 278, Issue 5, 3131-3136.

 

29

Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.

J.M.Binley, R.W.Sanders, A.Master, C.S.Cayanan, C.L.Wiley, L.Schiffner, B.Travis, S.Kuhmann, D.R.Burton, S.-L.Hu, W.C.Olson, J.P.Moore.

J.Virol (2002) : 76, 2606-2616

 

30

The mannose-dependent epitope for neutralising antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

R.W.Sanders, M.Venturi, L.Schiffner, R.Kalyanaraman, H.Katinger, K.O.Lloyd, P.D.Kwong, J.P.Moore.

J.Virol (2002) : 76, 7293-7305.

 

31

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilised human immunodeficiency virus type 1 gp140 envelope glycoprotein.

N.Schulke, M.S.Vesanen, R.W.Sanders, P.Zhu, M.Lu, D.J.Anselma, A.R.Villa, P.W.H.I.Parren, J.M.Binley, K.H.Roux, P.J.Maddon, J.P.Moore, W.C.Olson.

J.Virol (2002) : 76, 7760-7776

 

32

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilised human immunodeficiency virus type 1 gp140 envelope glycoprotein.

N.Schulke, M.S.Vesanen, R.W.Sanders, P.Zhu, M.Lu, D.J.Anselma, A.R.Villa, P.W.H.I.Parren, J.M.Binley, K.H.Roux, P.J.Maddon, J.P.Moore, W.C.Olson.

J.Virol (2002) : 76, 7760-7776

 

33

The alpha-glucosidase inhibitor 1- deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step

M.J Papandreou, R.Barbouche, R.Guieu, M.P.Kieny, E.Fenouillet.

Molecular Pharmacology (2002) : 61, Issue 1, 186-193.

 

34

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilised by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

J.M.Binley, R.W.Sanders, B.Clas, N.Schuelke, A.Master, Y.Guo, F.Kajumo, D.J.Anselma, P.J.Maddon, W.C.Olson, J.P.Moore.

J.Virol (2000) : 74, 627-643

 

35

Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection. 

D.S.Schiller, J.M.Binley, K.H.Roux, C.S.Adamson, I.M.Jones, H.-G.Krausslich, A.Hurley, M.Markowitz, J.P.Moore.

AIDS Res.Human Retroviruses (2000) : 16, 259-271

 

36

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilised by an intermolecular disulfide bond between the gp120 and gp41 subunits.

R.W.Sanders, L.Schiffner, A.Master, F.Kajumo, Y.Guo, T.Dragic, J.P.Moore, J.M.Binley

J.Virol (2000) : 74, 5091-5100

 

37

Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralisation resistance in a simian-human immunodeficiency virus passaged in vivo.

Y.Ye, Z.H.Si, J.P.Moore, J.Sodroski

 

38

Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type1 ?

Y.j.Zhang and J.P. Moore.

J.Virol (1999) : 73, 3443-3448

 

39

A cell-line based neutralisation assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 co-receptor.

A.Trkola, J.Matthews, C.Gordon, T.Ketas, J.P.Moore

J.Virol (1999) : 73, 8966-8974

 

40

Intracellular degradation of the HIV-1 envelope glycoprotein.

J.Courageot, E.Fenouillet, P.Bastiani, R.Miquelis.

Eur.J.Biochem (1999) : 260, 482-489

 

41

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

R.I.Connor, B.T.M.Korber, B.S.Graham, B.H.Hahn, D.D.Ho, B.D.Walker, A.U. Neumann, S.H.Vermund, J.Mestecky, S.Jackson, E.Fenamore, Y.Cao, F.Gao, S.Kalams, K.Kunstman, D.McDonald, N.McWilliams, A.Trkola, J.P.Moore, S.M.Wolinsky.

J.Virol (1998) : 72, 1552-1576

 

42

Analysis of the interaction of antibodies with a conserved, enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120.

J.M.Binley, R.Wyatt, E.Desjardins, P.D.Kwong, W.Hendrickson, J.P.Moore, J.Sodroski.

AIDS Res. Human Retroviruses (1998) : 14, 191-198

 

43

Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: Relationship to neutralisation. 

T.R.Fouts, A.Trkola, M.S.Fung, J.P.Moore

AIDS Res.Human Retroviruses (1998) : 14, 591-598.

 

44

CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein : Consequences for virus entry and neutralisation.

N.Sullivan, Y.Sun, Q.Sattentau, M.Thali, D.Wu, G.Denisova, J.Gershoni, J.Robinson, J.P.Moore, J.Sodroski.

J.Virol (1998) : 72, 4694-4703

 

45

Antibody neutralisation-resistant primary isolates of human immunodeficiency virus type 1.

P.W.H.I.Parren, M.Wang, A.Trkola, J.M.Binley, M.Purtscher, H.Katinger, J.P.Moore, D.R.Burton.

J.Virol (1998) : 72, 10270-10274

 

46

An investigation of the high avidity antibody response to the gp120 glycoprotein of human immunodeficiency virus type 1.

J.M.Binley, H.Arshad, T.R.Fouts, J.P.Moore.

AIDS Res.Human Retroviruses (1997) : 13, 1007-1016

 

47

Human immunodeficiency virus type 1 mutants that escape neutralisation by human monoclonal antibody IgG1b12.

H.Mo, L.Stamatatos, J.E.Ip, C.F.Barbas, P.W.H.I.Parren, D.R.Burton, J.P.Moore, D.D. Ho 

J.Virol (1997) : 71, 6869-6874

 

48

Demonstration of peripheral fucose units in N-linked glycans of human immunodeficiency virus type 1 gp120.

A.Bolmstedt, M.Biller, J-E.S.Hansen, J.P.Moore, S.Olofsson.

Arch.Virol. (1997) : 142, 2465-2481

 

49

Human immunodeficiency virus grown in CD4-expressing cells is associated with CD4.

Hartley C et al.

J.Gen.Virol ( Provisional acceptance pending review of revisions ) , (1996).

 

50

Biological properties of recombinant HIV envelope synthesised in CHO glycosylation mutant cell lines.

E.Fenouillet,R.Miquelis,R.Drillien.

Virology. (1996) ; 216 : 224-231

 

51

The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.

D.Chargelegue, C.M.Stanley, C.M.O’Toole, B.T.Colvin and M.W.Steward.

Clin Exp Immunol (1995) : 99 Pages 1-7.

 

52

Probing the Structure of the Human Immunodeficiency Virus Surface Glycoprotein gp120 with a Panel of Monoclonal Antibodies.

J.P. Moore, Quentin J. Sattentau et al.

Journal of Virology (1994), pages 469-484.

 

53

Exploration of Antigenic Variation in gp120 from Clades A through F of Human Immunodeficiency Virus Type 1 by using Monoclonal Antibodies.

John P.Moore, Francine E.Mc Cutchan et al.

Journal of Virology (1994) : Vol.68, No 12, p. 8350-8364.

 

54

Development of the anti-gp120 antibody response during seroconversion to Human Immunodeficiency virus type 1.

John P.Moore, Yunzhen CAO, David D.Ho and Richard A.Koup

Journal of Virology (1994) : Vol.68 No8, p 5142-5155

 

55

Extensive C-terminal deletion on HIV-1 env glycoproteins arising after a long term culture of chronically infected cells.

V.Zaides, M.Yagello, T.Veselovskaya, D.Schimtt, L.Rikova, E.Fenouillet, J.C.Gluckman.

Journal of General Virology (1994) ; 75 : 2963-2975.

 

56

Detecting SIV gp120 and its interaction with soluble CD4 by ELISA. 

J. P. Moore and Quentin J. Sattentau

AIDS Research and Human Retroviruses (1993) : Volume 9, No.12, pages 1297-1299.

 

57

Screening for inhibitors of HIV-gp120-CD4 binding using an enzyme linked immunosorbent assay.

Gilbert M.et al.

J.Virol Methods (1993) : 42 : 1-12.

 

58

Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain.

E.Fenouillet, I.Jones, B.Powell et al.

Journal of Virology (1993) : Vol 67, No. 1, Pages 150-160.

 

59

Human immunodeficiency virus type 1- encoded Vpu protein is phosphorylated by casein kinase 11.

Ulrich Schubert, Thomas Schneider et al.

European J. Biochem (1992) : 204, 875-883.

 

60

Immunological analysis of human immunodeficiency virus type 1 envelope glycosprotein proteolytic cleavage.

Emmanuel Fenouillet and Jean-Claude Gluckman.

Virology (1992) : 187, 825-828.

 

61

Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia Coli mediates dimerisation and enhances reverse transcription of retroviral RNA.

S.Weiss, B.Konig, Y.Morikawa, I.Jones.

Gene (1992) : 121, 203-212.

 

62

Complementation of human immunodeficiency virus glycoprotein mutations.in trans.

Y.Morikawa, J.P.Moore, E.Fenouillet, I.Jones.

Journal of General Virology (1992) : 73, 1907-1913.

 

63

Antigenicity of the HIV-2 V3 loop.

I.M.Jones, Y.Morikawa, E. Fenouillet, J.P.Moore.

AIDS (1992) : Vol.6, No8, Pages 888-889.

 

64

A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+cells.

J.P.Moore, Q.J.Sattentau, P.J. Klasse et al.

Journal of Virology (1992) : Vol 66, No.8, Pages 4784-4793.

 

65

Development of a sensitive ELISA for HIV-1-p24 antigen using a fluorogenic substrate for monitoring HIV-1 replication in vitro.

D.Chargelegue, C.M. O' Toole

Journal of Virological Methods (1992) : Vol. 38 ; 323-332.

 

66

Human immunodeficiency virus : novel enzyme-linked immunoassays for quantitation of envelope glycoprotein 120.

Weiler BE et al.

J.Virol Methods (1992) ; 32 : 287-301.

 

67

HIV-1-p24 antigen ELISA

J.P.Moore et al.

Journal of Virology (1991) ; 65 : 852-860.

 

68

Binding of recombinant HIV-1 and HIV-2 SU glycoproteins to sCD4.

J.P.Moore and Yuko Morikawa

Journal of Acquired Immune Deficiency Syndromes (1991) : Vol 4, No 4, Pages 442-443.

 

69

An enzyme-linked immunoassay for human immunodeficiency virus 1 envelope glycoprotein.

Gilbert M. et al.

Journal of Clinical Microbiology (1991) 29 : 142-147

 

70

Expression of HIV-1-gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro.

Y.Morikawa, H.A.Overton, J.P.Moore et al.

AIDS Research and Human Retroviruses (1990) Vol 6, No 6, Pages 765-773.

 

71

An Enzyme linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1.

J.P.Moore, L.A.Wallace et al.

AIDS (1989) ; 3 : 155-163

 

72

Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1.

J.P.Moore and Ruth F.Jarrett

AIDS Research and Human Retroviruses (1988) : Vol 4, No 5, Pages 369-379.